AGTC - アプライド・ジェネティック・テクノロジ―ズ （Applied Genetic Technologies Corporation） アプライド・ジェネティック・テクノロジ―ズAGTCのチャート
AGTCの企業情報
| symbol | AGTC |
|---|---|
| 会社名 | Applied Genetic Technologies Corp （アプライド・ジェネティック・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31 2016 its product candidates included treatments for X-linked retinoschisis (XLRS) over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31 2016 the Company was engaged in developing three discovery programs targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss extreme light sensitivity resulting in daytime blindness and reduced or complete loss of color discrimination achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1). アプライド・ジェネティック・テクノロジ―ズは、米国のバイオ医薬品企業。臨床段階で、眼科と肺疾患のための遺伝子治療医薬品の開発に従事する。主要な開発段階の医薬品は、X連鎖網膜分離症(XLRS)、色覚異常(ACHM)、およびX連鎖網膜色素変性症(XLRP)の治療向けを含む。本社はフロリダ州。 Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. |
| 本社所在地 | 14193 N.W. 119th Terrace Suite 10 Alachua FL 32615 USA |
| 代表者氏名 | Scott Koenig スコットケーニッヒ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 386-462-2204 |
| 設立年月日 | 36161 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.agtc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/agtc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.20900 |
| 終値（lastsale） | 6.55 |
| 時価総額（marketcap） | 118745919.4 |
| 時価総額 | 時価総額（百万ドル） 115.30140 |
| 売上高 | 売上高（百万ドル） 24.18600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 10.39640 |
| 当期純利益 | 当期純利益（百万ドル） -22.09100 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Applied Genetic Technologies Corp revenues decreased 39% to $24.2M. Net loss before extraordinary items totaled $22.1M vs. income of $407K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Other expense increase from $47K to $125K (expense). |
AGTCのテクニカル分析
AGTCのニュース
Most supply chain managers expect problems to continue at least through 2024 2022/12/24 12:29:42 Kwhen Finance
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation 2022/12/01 12:00:00 GlobeNewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled to receive $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.
Applied Genetic Technologies Said Syncona Limited Extended Offer to Purchase All Shares at $0.34/Sh 2022/11/29 13:14:02 Investing.com
https://www.investing.com/news/pro/applied-genetic-technologies-said-syncona-limited-extended-offer-to-purchase-all-shares-at-034sh-432SI-2953637
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation | MarketScreener 2022/11/29 13:03:02 MarketScreener
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 -- Applied Genetic Technologies Corporation , announced today that a portfolio company of Syncona Limited has extended the expiration of its… | November 29, 2022
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation 2022/11/29 13:00:00 GlobeNewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.
Most supply chain managers expect problems to continue at least through 2024 2022/12/24 12:29:42 Kwhen Finance
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation 2022/12/01 12:00:00 GlobeNewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled to receive $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.
Applied Genetic Technologies Said Syncona Limited Extended Offer to Purchase All Shares at $0.34/Sh 2022/11/29 13:14:02 Investing.com
https://www.investing.com/news/pro/applied-genetic-technologies-said-syncona-limited-extended-offer-to-purchase-all-shares-at-034sh-432SI-2953637
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation | MarketScreener 2022/11/29 13:03:02 MarketScreener
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 -- Applied Genetic Technologies Corporation , announced today that a portfolio company of Syncona Limited has extended the expiration of its… | November 29, 2022
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation 2022/11/29 13:00:00 GlobeNewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday 2022/10/25 09:55:28 Benzinga
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC ) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. Vaxcyte, Inc. (NASDAQ: PCVX ) shares surged 60.4% to close at $33.00 on Monday after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24. Mullen Automotive, Inc. (NASDAQ: MULN ) climbed 32.9% to close at $0.50 after the company announced it has secured exclusive sales, distribution and branding rights to the I-GO, which is fully EU Standard homologated and certified for sale in select European markets. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) climbed 24.8% to close at $0.4741. Motus GI Holdings, Inc. (NASDAQ: MOTS ) climbed 23.1% to close at $1.97 after the company announced clinical data for Pure-Vu EVS in three poster presentations at the American College of Gastroenterology 2022 Annual Scientific Meeting.
US stocks closed higher, Dow Jones up 1.34% 2022/10/25 03:19:29 InstaForex
At the close of the New York Stock Exchange, the Dow Jones rose 1.34% to a one-month high, the S&P 500 was up 1.19% and the NASDAQ Composite was up 0.86%. Amgen Inc was the top performer among the components of the Dow Jones index today, up 9.38 points or 3.72% to close at 261.32. Quotes Coca-Cola Co rose by 1.61 points (2.88%), ending trading at 57.57. Home Depot Inc rose 7.73 points or 2.81% to close at 283.26. The least gainers were Nike Inc, which lost 0.49 points or 0.55% to end the session at 88.01. The Walt Disney Company (NYSE:DIS) was up 0.32 points or 0.31% to close at 101.72, while Chevron Corp was down 0.06 points or 0.03% to end the trading at 173.13. Leading gainers among the S&P 500 index components in today''s trading were HCA Holdings Inc, which rose 7.02% to hit 210.47, Tractor Supply Company, which gained 5.30% to close at 207.83, and also shares of Regions Financial Corporation, which rose 5.28% to close the session at 20.55. The least gainers were Las Vegas Sands Corp, which shed 10.29% to close at 35.05.
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points 2022/10/24 19:44:06 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. The Dow traded up 1.50% to 31,547.65 while the NASDAQ rose 1.04% to 10,972.47. The S&P 500 also rose, gaining, 1.38% to 3,804.48. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 2.1% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and IMARA Inc. (NASDAQ: IMRA ). In trading on Monday, materials shares fell by 0.3%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 67% to $34.29 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24. Shares of Applied Genetic Technologies Corporation (NASDAQ: AGTC ) got a boost, shooting 60% to $0.3845 after Syncona announced it …
Applied Genetic Technologies Corporation (NASDAQ:AGTC) stock: You might be surprised 2022/10/24 17:16:00 US Post News
Applied Genetic Technologies Corporation (AGTC)’s stock is trading at $0.38 at the moment marking a rise of 58.25% from the last session close. As of this writing, shares are priced at -88.05% less than their 52-week high of $3.18, and 64.98% over their 52-week low of $0.23. Based on the past 30-day period, the stock […]
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday''s Mid-Day Session 2022/10/24 16:30:04 Benzinga
Gainers Vaxcyte, Inc. (NASDAQ: PCVX ) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24. Healthcare Triangle, Inc. (NASDAQ: HCTI ) gained 54.8% to $0.6000. Applied Genetic Technologies Corporation (NASDAQ: AGTC ) climbed 54.1% to $0.3701. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. Motus GI Holdings, Inc. (NASDAQ: MOTS ) gained 40% to $2.2450 after the company announced clinical data for Pure-Vu EVS in three poster presentations at the American College of Gastroenterology 2022 Annual Scientific Meeting. Mullen Automotive, Inc. (NASDAQ: MULN ) rose 31.8% to $0.4957 after the company announced it has secured exclusive sales, distribution and branding rights to the I-GO, which is fully EU Standard homologated and certified for sale in select European markets. Enservco Corporation (NYSE: ENSV ) gained 21.3% to $2.4499.